Table 2 Adjusted hazard ratios (HR) for non-persistence and 95% confidence intervals (CI) in the Cox regression model
Adjusted HR | 95% CI | |
|---|---|---|
Study group (ref. 120 mg Gb dosage strength) | ||
240 mg Gb dosage strength | 0.64 * | 0.57-0.71 |
< 120 mg Gb dosage strength | 4.36 * | 4.18-4.54 |
Medical specialty of initial prescriber (ref.: general practitioner) | ||
Neurologist | 0.93 * | 0.89-0.97 |
Internist | 0.96 | 0.91-1.01 |
Other | 1.43 * | 1.36-1.50 |
Region of initial prescriber (ref.: Western Germany) | ||
Eastern Germany | 0.74 * | 0.71-0.77 |
Insurance membership status (ref.: retired) | ||
Mandatory member | 1.23 * | 1.17-1.29 |
Family member | 1.61 * | 1.50-1.73 |
Pre-treatment 180 days prior to index date (ref.: none) | ||
Antidepressants | 0.97 | 0.93-1.01 |
Antidementia drugs | 0.86 * | 0.81-0.91 |
Nootropics | 0.92 | 0.85-1.00 |
Antivertigo preparations (betahistine/flunarizine/cinnarizine) | 0.99 | 0.94-1.05 |
Pentoxifylline | 1.07 | 0.99-1.15 |
Drugs for treatment of peripheral arterial occlusive disease (cilostazol/naftidrofuryl) | 0.99 | 0.89-1.10 |
Number of different ATC third level drugs prescribed within 180 days prior to index date | 1.00 | 1.00-1.00 |